Research programme: protein tyrosine phosphatase beta inhibitors - Akebia

Drug Profile

Research programme: protein tyrosine phosphatase beta inhibitors - Akebia

Alternative Names: HPTPβ inhibitors - Akebia

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Vascular disorders

Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in USA
  • 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Vascular disorders presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 07 Jan 2010 Protein tyrosine phosphatase beta inhibitors are available for licensing (http://www.akebia.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top